THE HYDRATION PHARMACEUTICALS COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.013 AUD | 0.00% |
|
0.00% | -45.83% |
| 10/05 | The Hydration Pharmaceuticals Issues Shares as Interest Prepayment | MT |
| 01/05 | The Hydration Pharmaceuticals' Revenue Falls 14% in March Quarter | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 35.02 | 9.942 | 4.333 |
| Enterprise Value (EV) 1 | 24.35 | 8.966 | 6.386 |
| P/E ratio | -1.84 x | -0.93 x | -0.39 x |
| Yield | - | - | - |
| Capitalization / Revenue | 5.72 x | 1.09 x | 0.43 x |
| EV / Revenue | 3.97 x | 0.99 x | 0.64 x |
| EV / EBITDA | -4.48 x | -0.84 x | - |
| EV / FCF | -56,79,137 x | -16,35,483 x | -22,03,782 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 2.65 x | 2.5 x | -12.1 x |
| Nbr of stocks (in thousands) | 1,61,027 | 1,63,755 | 2,65,142 |
| Reference price 2 | 0.2175 | 0.0607 | 0.0163 |
| Announcement Date | 31/03/22 | 31/03/23 | 28/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4.161 | 2.963 | 3.757 | 6.127 | 9.1 | 10.04 |
| EBITDA 1 | -9.18 | -3.389 | -3.276 | -5.437 | -10.7 | - |
| EBIT 1 | -9.257 | -3.4 | -3.3 | -5.44 | -10.7 | -7.742 |
| Operating Margin | -222.47% | -114.77% | -87.84% | -88.79% | -117.6% | -77.1% |
| Earnings before Tax (EBT) 1 | -9.602 | -3.434 | -0.7437 | -8.952 | -10.61 | -8.102 |
| Net income 1 | -9.602 | -3.434 | -0.7437 | -8.952 | -10.61 | -8.102 |
| Net margin | -230.76% | -115.91% | -19.8% | -146.1% | -116.56% | -80.69% |
| EPS | - | -0.0605 | -0.0131 | -0.1185 | -0.0652 | -0.0415 |
| Free Cash Flow | - | -1.517 | 0.0887 | -4.287 | -5.482 | -2.898 |
| FCF margin | - | -51.21% | 2.36% | -69.97% | -60.24% | -28.86% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 10/12/21 | 10/12/21 | 10/12/21 | 31/03/22 | 31/03/23 | 28/03/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 2.05 |
| Net Cash position 1 | 2.52 | 2.73 | 1.64 | 10.7 | 0.98 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -1.52 | 0.09 | -4.29 | -5.48 | -2.9 |
| ROE (net income / shareholders' equity) | - | -137% | -33.9% | -118% | -123% | -447% |
| ROA (Net income/ Total Assets) | - | -50.4% | -47.7% | -34.4% | -52.1% | -56.7% |
| Assets 1 | - | 6.819 | 1.559 | 26 | 20.37 | 14.3 |
| Book Value Per Share | - | 0.0400 | 0.0400 | 0.0800 | 0.0200 | -0 |
| Cash Flow per Share | - | 0.0500 | 0.0300 | 0.0700 | 0.0300 | 0.0100 |
| Capex | - | 0.02 | 0.02 | - | - | - |
| Capex / Sales | - | 0.69% | 0.48% | - | - | - |
| Announcement Date | 10/12/21 | 10/12/21 | 10/12/21 | 31/03/22 | 31/03/23 | 28/03/24 |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -45.83% | 23.04L | |
| +32.09% | 69TCr | |
| +29.39% | 58TCr | |
| -1.34% | 37TCr | |
| +20.34% | 33TCr | |
| +7.39% | 29TCr | |
| +14.25% | 24TCr | |
| -3.03% | 21TCr | |
| +10.02% | 21TCr | |
| +8.49% | 17TCr |
- Stock Market
- Equities
- HPC Stock
- Financials The Hydration Pharmaceuticals Company Limited
